Serina Therapeutics, Inc.SERNYSE
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
15.29%
↑ 62% above average
Average (34q)
9.41%
Historical baseline
Range
High:128.00%
Low:-72.18%
Volatility
2126.7%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 15.29% |
| Q2 2025 | 6.81% |
| Q1 2025 | 24.78% |
| Q4 2024 | -2.07% |
| Q3 2024 | 51.51% |
| Q2 2024 | 44.12% |
| Q1 2024 | 21.94% |
| Q4 2023 | 64.91% |
| Q3 2023 | 14.82% |
| Q2 2023 | 20.05% |
| Q1 2023 | 128.00% |
| Q4 2022 | 35.66% |
| Q3 2022 | -42.92% |
| Q2 2022 | -37.74% |
| Q1 2022 | 5.83% |
| Q4 2021 | 41.15% |
| Q3 2021 | -45.76% |
| Q2 2021 | 53.95% |
| Q1 2021 | -72.18% |
| Q4 2020 | 49.64% |
| Q3 2020 | -42.28% |
| Q2 2020 | -17.22% |
| Q1 2020 | 10.00% |
| Q4 2019 | 1.76% |
| Q3 2019 | -13.44% |
| Q2 2019 | 12.86% |
| Q1 2019 | -3.25% |
| Q4 2018 | 14.39% |
| Q3 2018 | -5.32% |
| Q2 2018 | -13.95% |
| Q1 2018 | 27.82% |
| Q4 2017 | -18.41% |
| Q3 2017 | 24.93% |
| Q2 2017 | -26.23% |
| Q1 2017 | 0.00% |